Publications

Our research has been featured in Nature, Nature Medicine, Cancer Cell, Molecular Therapy, and other journals.

2022

D.B. Goodman*, C.S. Azimi*, K. Kearns, A. Talbot, K. Garakani, J. Garcia, N. Patel, B. Hwang, D. Lee, E. Park, V.S. Vykunta, B.R. Shy, C.J. Ye, J. Eyquem, A. Marson, J.A. Bluestone, K.T. Roybal. Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies. Science Translational Medicine (2022). *Equal contributions


M.T. Witkowski*^, S. Lee*, E. Wang*, A.K. Lee, A. Talbot, C. Ma, N. Tsopoulidis, J. Brumbaugh, Y. Zhao, K.G. Roberts, S.J. Hogg, S. Nomikou, Y.E. Ghebrechristos, P. Thandapani, C.G. Mullighan, K. Hochedlinger, W. Chen, O. Abdel-Wahab, J. Eyquem, I. Aifantis^. NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nature Immunology (2022). *Equal contributions, ^Co-corresponding authors


J. Carnevale*^, E. Shifrut*^, N. Kale, W.A. Nyberg, F. Blaeschke, Y.Y. Chen, Z. Li, S.P. Bapat, M.E. Diolaiti, P. O’Leary, S. Vedova, J. Belk, B. Daniel, T.L. Roth, S. Bachl, A.A. Anido, B. Prinzing, J. Ibañez-Vega, S. Lange, D. Haydar, M. Luetke-Eversloh, M. Born-Bony, B. Hegde, S. Kogan, T. Feuchtinger, H. Okada, A.T. Satpathy, K. Shannon, S. Gottschalk, J. Eyquem^, G. Krenciute^, A. Ashworth^, A. Marson^. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature (2022). *Equal contributions, ^Co-corresponding authors


B.R. Shy*^, V.S. Vykunta*, A. Ha, A. Talbot, T.L. Roth, D.N. Nguyen, W.G. Pfeifer, Y.Y. Chen, F. Blaeschke, E. Shifrut, S. Vedova, M.R. Mamedov, J.-Y. Chung, H. Li, R. Yu, D. Wu, J. Wolf, T.G. Martin, C.E. Castro, L. Ye, J.H. Esensten, J. Eyquem, A. Marson^. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nature Biotechnology (2022). *Equal contributions, ^Co-corresponding authors


S.J.C. van der Stegen, P.L. Lindenbergh, R.M. Petrovic, H. Xie, M.P. Diop, V. Alexeeva, Y. Shi, J. Mansilla-Soto, M. Hamieh, J. Eyquem, A. Cabriolu, X. Wang, R. Abujarour, T. Lee, R. Clarke, B. Valamehr, M. Themeli, I. Riviere, M. Sadelain. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature Biomedical Engineering (2022).


F. Blaeschke, Y.Y. Chen, R. Apathy, Z. Li, C.T. Mowery, W.A. Nyberg, A. To, R. Yu, R. Bueno, M.C. Kim, R. Schmidt, D.B. Goodman, T. Feuchtinger, J. Eyquem, C.J. Ye, E. Shifrut, T.L. Roth, A. Marson. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. bioRxiv (2022).


I.D. Ferguson, B. Patiño-Escobar, S.T. Tuomivaara, Y.-H.T. Lin, M.A. Nix, K.K. Leung, C. Kasap, E. Ramos, W.N. Vasquez, A. Talbot, M. Hale, A. Naik, A. Kishishita, P. Choudhry, A. Lopez-Girona, W. Miao, S.W. Wong, J.L. Wolf, T.G. Martin III, N. Shah, S. Vandenberg, S. Prakash, L. Besse, C. Driessen, A.D. Posey Jr., R.D. Mullins, J. Eyquem, J.A. Wells, A.P. Wiita. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nature Communications 13 (2022).


W.A. Nyberg, J. Eyquem. Genome editing applications in cancer T cell therapy. Chapter in Genome Editing in Drug Discovery (2022).


J. Mansilla-Soto*,  J. Eyquem*,  S. Haubner,  M. Hamieh,  J. Feucht, N. Paillon, A.E. Zucchetti, Z. Li, M. Sjöstrand, P.L. Lindenbergh, M. Saetersmoen, A. Dobrin,  M. Maurin, A. Iyer, A.G. Angus, M.M. Miele, Z. Zhao, T. Giavridis, S.J.C. van der Stegen , F. Tamzalit, I. Rivière, M. Huse , R.C. Hendrickson, C. Hivroz, M. Sadelain. HLA-independent T cell receptors for targeting tumors with low antigen density. Nature Medicine 28, 345–352 (2022). *Equal contributions

 

2021

Y.D. Muller, D.P. Nguyen, L.M.R. Ferreira, P. Ho, C. Raffin, R.V.B. Valencia, Z. Congrave-Wilson, T.L. Roth, J. Eyquem, F. Van Gool, A. Marson, L. Perez, J.A. Wells, J.A. Bluestone, Q. Tang. The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28. Front Immunol 12:639818 (2021).

 

2019 

M. Hamieh, A. Dobrin, A. Cabriolu, S.J.C. van der Stegen, T. Giavridis, J. Mansilla-Soto, J. Eyquem, Z. Zhao, B.M. Whitlock, M.M. Miele, Z. Li, K.M. Cunanan, M. Huse, R.C. Hendrickson, X. Wang, I. Rivière, M. Sadelain. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112–116 (2019).

 

J. Feucht*, J. Sun*, J. Eyquem, Y.-J. Ho, Z. Zhao, J. Leibold, A. Dobrin, A. Cabriolu, M. Hamieh, M. Sadelain. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature Medicine 25, 82–88 (2019). *Equal contributions

 

2018

S. Krebs, A. Ahad, L.M. Carter, J. Eyquem, C. Brand, M. Bell, V. Ponomarev, T. Reiner, C.F. Meares, S. Gottschalk, M. Sadelain, S.M. Larson, W.A. Weber. Antibody with infinite affinity for in vivo tracking of genetically engineered lymphocytes. Journal of Nuclear Medicine 59, 1894–1900 (2018).


C. DeSelm, M.L. Palomba, J. Yahalom, M. Hamieh, J. Eyquem, V.K. Rajasekhar, M. Sadelain. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Molecular Therapy 26, 2542–2552 (2018).


T. Giavridis, S.J.C. van der Stegen, J. Eyquem, M. Hamieh, A. Piersigilli, M. Sadelain. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature Medicine 24, 731–738 (2018).

 

2017

F. Perna, S.H. Berman, R.K. Soni, J. Mansilla-Soto, J. Eyquem, M. Hamieh, R.C. Hendrickson, C.W. Brennan, M. Sadelain. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32, 506–519.e5 (2017).


J. Eyquem*, J. Mansilla-Soto*, T. Giavridis, S.J.C. van der Stegen, M. Hamieh, K.M. Cunanan, A. Odak, M. Gönen, M. Sadelain. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017). *Equal contributions

 

Prior to 2017 

L. Poirot, B. Philip, C. Schiffer-Mannioui, D. Le Clerre, I. Chion-Sotinel, S. Derniame, P. Potrel, C. Bas, L. Lemaire, R. Galetto, C. Lebuhotel, J. Eyquem, G.W.-K. Cheung, A. Duclert, A. Gouble, S. Arnould, K. Peggs, M. Pule, A.M. Scharenberg, J. Smith. Multiplex genome-edited T-cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Research 75, 3853–3864 (2015).

 

X. Duportet, L. Wroblewska, P. Guye, Y. Li, J. Eyquem, J. Rieders, T. Rimchala, G. Batt^, R. Weiss^. A platform for rapid prototyping of synthetic gene networks in mammalian cells. Nucleic Acids Research 42, 13440–13451 (2014). ^Co-corresponding authors


J. Eyquem, L. Poirot, R. Galetto, A.M. Scharenberg, J. Smith. Characterization of three loci for homologous gene targeting and transgene expression. Biotechnology and Bioengineering 110, 2225–2235 (2013)

Featured In

News

Media highlights of Eyquem Lab's research.
HIT-T cell paper highlighted in Cancer Cell
Read More >>
Response to Low Antigen Density Is Improved by HLA-Independent T-cell Receptors
Read More >>
CRISPR-driven CARs
Read More >>
CRISPR genome editing and immunotherapy – the early adopter
Read More >>
CRISPR gene therapy is enhancing T-cell immunotherapy treatment of cancer and treatments in people could be available within 2 to 3 years
Read More >>
Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors
Read More >>
Using CRISPR to Supercharge Cancer-Killing Immune Cells
Read More >>
AACR 2018: An off-the-shelf, dual-targeted CAR T-cell product showed promising results in preclinical studies
Read More >>
Curing Cancer with CRISPR
Read More >>
Pancreatic cancer cells digest extracellular protein
Read More >>

Stay Updated

Keep up-to-date with the latest research from the Eyquem lab.

Join us in Austin to learn more about immunotherapy with an amazing line up of speakers!

Congrats to @indeelabs and excited to collaborate!

Another exciting study from the @Satpathology lab!

Schedule an Interview

Contact us to set up an interview with Justin Eyquem.